Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents

J Sasadeusz; A Grigg; PD Hughes; S Lee Lim; M Lucas; G McColl; SA McLachlan; MG Peters; N Shackel; M Slavin; V Sundararajan; A Thompson; J Doyle; J Rickard; P De Cruz; RG Gish; K Visvanathan

Journal article

Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents

J Sasadeusz, A Grigg, PD Hughes, S Lee Lim, M Lucas, G McColl, SA McLachlan, MG Peters, N Shackel, M Slavin, V Sundararajan, A Thompson, J Doyle, J Rickard, P De Cruz, RG Gish, K Visvanathan

Clinics in Liver Disease | W B SAUNDERS CO-ELSEVIER INC | Published : 2019

DOI: 10.1016/j.cld.2019.04.012

Abstract

Because of the relatively high prevalence of both hepatitis B infection and various forms of autoimmune inflammatory diseases treated with aggressive immunotherapy, reactivation of hepatitis B occurs in a substantial number of patients. The risk of reactivation depends on the degree and duration of immunosuppression. A large number of drug treatments have resulted in reactivation of hepatitis B virus infection and, based on the mechanisms and extent of immunosuppression, recommendations for some of the newer classes of immunosuppressive drugs are provided.

University of Melbourne Researchers

Joseph Sasadeusz Author

Peter Hughes Author

Geoff McColl Author

Sue-Anne McLachlan Author

Grants

Funding Acknowledgements

Meetings to discuss and develop recommendations presented in this manuscript and medical writing services provided in the preparation of this manuscript were funded by Gilead Sciences. Neither the medical writer or Gilead in any way influenced the content or the conclusions of the position paper. None of the authors had any direct financial support from Gilead Sciences or any other companies.